Literature DB >> 7544987

Interleukin-6 and acute-phase proteins in head and neck cancer.

O Gallo1, A M Gori, M Attanasio, F Martini, B Giusti, T Brunelli, E Gallina.   

Abstract

The acute-phase response is the answer of the organism to a disturbance of its homeostasis and is characterized by dramatic changes in the concentration of some plasma proteins defined as acute-phase proteins. In recent years several data have shown that interleukin-6 (IL-6) is the major inducer of acute-phase protein synthesis in human hepatocytes. Recently, we demonstrated higher IL-6 serum levels in head and neck cancer (HNC) patients than in healthy subjects. In the present study we examined the relationship between levels of IL-6 and of several acute-phase proteins, including C-reactive protein (CRP), alpha 1-antitrypsin (ATT), alpha 1-acid glycoprotein (AAG), haptoglobin (HPT) and fibrinogen. Eighteen patients were studied and had squamous cell carcinoma of the larynx (n = 9), oral cavity (n = 4), oropharynx (n = 3) and hypopharynx (n = 2). Proteins were measured at three time points before and three time points after surgery. Significant (P < 0.0001) relationships were found between IL-6 and CRP (r = 0.69), and fibrinogen (r = 0.51), whereas no correlation was found with AAT (r = 0.13, P = 0.56), AAG (r = 0.38; P = 0.07) and HPT (r = 0.16; P = 0.46). These data strongly suggest that IL-6 may play a key role in acute-phase protein synthesis in HNC and in regulation of the complex host response to malignancies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544987     DOI: 10.1007/bf00178104

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  29 in total

1.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Immunosuppressive properties of electrophoretically "slow" and "fast" form alpha 2-macroglobulin. Effects on cell-mediated cytotoxicity and (allo-) antigen-induced T cell proliferation.

Authors:  C M Petersen; E Ejlersen; S K Moestrup; P H Jensen; O Sand; L Sottrup-Jensen
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

4.  Serum levels of IL-1, IL-6 and tumour necrosis factors in patients undergoing coronary artery bypass grafts or cholecystectomy.

Authors:  N Lahat; A Y Zlotnick; R Shtiller; I Bar; G Merin
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

5.  Acute phase reactant proteins--an aid to monitoring surgical treatment of laryngeal carcinoma.

Authors:  T Krecicki; M Leluk
Journal:  J Laryngol Otol       Date:  1992-07       Impact factor: 1.469

6.  Characterization of a novel cell line from pleomorphic adenoma of the parotid gland with myoepithelial phenotype and producing interleukin-6 as an autocrine growth factor.

Authors:  O Gallo; D Bani; G Toccafondi; F Almerigogna; O F Storchi
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

7.  Preoperative and postoperative cytokines in patients with cancer.

Authors:  H Nakazaki
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

8.  Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity.

Authors:  A M Baskies; P B Chretien; J F Weiss; R W Makuch; R A Beveridge; W J Catalona; H E Spiegel
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

9.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  10 in total

1.  Clinical relevance of a new pre-treatment laboratory prognostic index in patients with oral squamous cell carcinoma.

Authors:  M Grimm; M Lazariotou
Journal:  Med Oncol       Date:  2011-08-19       Impact factor: 3.064

2.  Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytes.

Authors:  Aroonwan Lam-ubol; Dustin Hopkin; Elena M Letuchy; Zoya B Kurago
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

3.  C-reactive protein levels: a prognostic marker for patients with head and neck cancer?

Authors:  Astrid L Kruse; Heinz T Luebbers; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2010-08-02

4.  Evaluation of white blood cell count as a possible prognostic marker for oral cancer.

Authors:  Astrid L Kruse; Heinz T Luebbers; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2011-02-27

5.  Using SCC antigen and CRP levels as prognostic biomarkers in recurrent oral cavity squamous cell carcinoma.

Authors:  I-How Chen; Chun-Ta Liao; Hung-Ming Wang; Jung-Ju Huang; Chung-Jan Kang; Shiang-Fu Huang
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

6.  C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma.

Authors:  Heung-Chul Park; Moon-Young Kim; Chul-Hwan Kim
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2016-10-25

7.  Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades.

Authors:  Celeste Sánchez-Romero; Ronell Bologna-Molina; Rogelio González-González; Sirced Salazar-Rodríguez; Nataly Barreiro Mendoza
Journal:  J Oral Maxillofac Pathol       Date:  2021-08-31

Review 8.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

9.  Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma.

Authors:  Hsuan-Ho Chen; Hung-Ming Wang; Kang-Hsing Fan; Chien-Yu Lin; Tzu-Chen Yen; Chun-Ta Liao; I-How Chen; Chung-Jan Kang; Shiang-Fu Huang
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis.

Authors:  Yanglan Chen; Rong Cong; Chengjian Ji; Wenhua Ruan
Journal:  Cancer Med       Date:  2020-11-17       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.